DrilonALaetschTWKummarS, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731-739.
2.
DoebeleRCDrilonAPaz-AresL, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21(2):271-282.
ZhaoPLiLJiangXLiQ.Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J Hematol Oncol. 2019;12(1):54. doi:10.1186/s13045-019-0738-1
6.
TannockIFHickmanJA.Limits to personalized cancer medicine. N Engl J Med. 2016;375(13):1289-1294.
7.
CollinsFSVarmusH.A new initiative on precision medicine. N Engl J Med. 2015;372(9):793-795.
8.
Meric-BernstamFJohnsonAHollaV, et al. A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst. 2015;107(7):djv098.
NormannoNDe LucaAAbateRE, et al. Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study. Eur J Cancer. 2023;187:174-184. doi:10.1016/j.ejca.2023.03.027
11.
CummingsJLeeGRitterAZhongK.Alzheimer’s disease drug development pipeline: 2021. Alzheimers Dement (NY). 2021;7(1):e12179.
12.
TopolEJ.High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56.
13.
ZhouPYangXLWangXG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273.
